FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. A

Go back to FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
(NASDAQ: ARQT) Delayed: 24.83 -0.31 (1.23%)
Previous Close $25.14    52 Week High $ 
Open $24.95    52 Week Low $ 
Day High $25.15    P/E N/A 
Day Low $24.60    EPS $ 
Volume 380,691